Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
Hutchmed (China)
HCM
Precision Drilling
PDS
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -6.26%2.18B | -1.23%525.61M | -2.74%546.84M | -4.06%556.41M | -15.35%551.42M | -16.14%2.33B | -15.15%532.13M | -21.82%562.23M | -22.84%579.98M | -3.53%651.44M |
Operating revenue | -6.26%2.18B | -1.23%525.61M | -2.74%546.84M | -4.06%556.41M | -15.35%551.42M | -16.14%2.33B | -15.15%532.13M | -21.82%562.23M | -22.84%579.98M | -3.53%651.44M |
Cost of revenue | -6.84%1.91B | 0.68%468.91M | -4.04%471.16M | -5.20%486.85M | -16.74%481.14M | -12.70%2.05B | -16.75%465.73M | -18.26%490.99M | -17.17%513.58M | 2.09%577.88M |
Gross profit | -1.94%272.21M | -14.62%56.7M | 6.25%75.69M | 4.75%69.55M | -4.46%70.28M | -35.00%277.6M | -2.00%66.41M | -39.87%71.24M | -49.55%66.4M | -32.65%73.56M |
Operating expense | -1.40%201.73M | -14.95%49M | 12.25%51.74M | 4.67%50.47M | -4.27%50.11M | -6.43%204.6M | 2.52%57.61M | -27.67%46.09M | -8.88%48.22M | 14.24%52.35M |
Selling and administrative expenses | 1.65%143.91M | -4.45%35.78M | 8.45%37.65M | 7.83%35.98M | -4.56%34.08M | -12.18%141.57M | 4.61%37.45M | -29.05%34.72M | -15.80%33.37M | -3.10%35.71M |
-Selling and marketing expense | -5.66%45.63M | -11.00%11.02M | -3.53%11.39M | 6.47%11.83M | -12.85%11.39M | -18.06%48.37M | -5.65%12.38M | -21.67%11.81M | -28.57%11.11M | -14.47%13.07M |
-General and administrative expense | 5.45%98.28M | -1.22%24.76M | 14.63%26.25M | 8.50%24.15M | 0.23%22.69M | -8.78%93.2M | 10.55%25.07M | -32.33%22.9M | -7.56%22.26M | 4.95%22.64M |
Research and development costs | -5.70%55.67M | -9.96%13.79M | -6.53%13.53M | -0.09%14.09M | -5.83%14.26M | -11.40%59.04M | -7.39%15.32M | -14.48%14.48M | -15.49%14.11M | -8.10%15.14M |
Other operating expenses | -45.96%2.16M | -111.85%-574K | 117.93%556K | -46.84%395K | 18.38%1.78M | 143.44%3.99M | 25.59%4.84M | -45.52%-3.1M | 121.81%743K | 120.02%1.5M |
Operating profit | -3.45%70.48M | -12.48%7.7M | -4.76%23.95M | 4.97%19.08M | -4.93%20.17M | -64.97%73M | -23.96%8.79M | -54.07%25.15M | -76.90%18.18M | -66.54%21.21M |
Net non-operating interest income expense | -17.18%-14.18M | -98.81%-4.83M | -21.23%-3.62M | 31.15%-2.66M | -8.82%-3.07M | -23.39%-12.1M | 4.93%-2.43M | -34.49%-2.99M | -41.73%-3.87M | -22.38%-2.82M |
Non-operating interest income | ---- | ---- | ---- | ---- | ---- | 255.83%3.84M | ---- | ---- | ---- | ---- |
Non-operating interest expense | -11.06%14.18M | --4.83M | ---- | ---- | ---- | 46.44%15.95M | ---- | ---- | ---- | ---- |
Total other finance cost | ---- | ---- | 21.23%3.62M | -31.15%2.66M | 8.82%3.07M | ---- | ---- | 34.49%2.99M | 41.73%3.87M | 22.38%2.82M |
Other net income (expense) | 133.11%4.14M | 95.91%-410K | 115.65%989K | -60.81%783K | 56.32%2.36M | -26.37%-12.51M | -3,399.01%-10.03M | -204.92%-6.32M | 131.08%2M | 188.78%1.51M |
Gain on sale of security | ---- | ---- | 156.62%577K | -61.62%783K | 46.22%1.95M | 115.80%1.47M | -201.26%-886K | 57.08%-1.02M | 135.41%2.04M | 165.38%1.34M |
Special income (charges) | --0 | --0 | --0 | --0 | --0 | -989.11%-14.01M | -9,754.22%-8.18M | -6,017.39%-5.63M | 96.03%-42K | -201.92%-157K |
-Less:Restructuring and merger&acquisition | --0 | --0 | --0 | --0 | --0 | 3,785.71%11.97M | 7,298.80%6.14M | 6,017.39%5.63M | -48.15%42K | 201.92%157K |
-Less:Impairment of capital assets | --0 | --0 | ---- | ---- | ---- | 108.38%2.04M | ---- | ---- | ---- | ---- |
-Gain on sale of business | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 14,689.29%4.14M | 57.47%-410K | 25.23%412K | ---- | 23.12%410K | -95.94%28K | -97.54%-964K | -16.50%329K | ---- | -15.05%333K |
Income before tax | 24.90%60.44M | 166.99%2.46M | 34.58%21.32M | 5.47%17.21M | -2.23%19.46M | -74.36%48.39M | -139.37%-3.67M | -68.61%15.84M | -76.54%16.31M | -66.49%19.9M |
Income tax | 22.99%10.07M | 63.85%-894K | -170.02%-2.29M | 111.71%7.69M | 48.02%5.57M | -80.30%8.19M | -62.38%-2.47M | -70.48%3.27M | -79.16%3.63M | -74.21%3.76M |
Net income | 25.29%50.37M | 380.80%3.35M | 87.78%23.61M | -24.94%9.52M | -13.93%13.89M | -72.68%40.2M | -111.01%-1.19M | -68.08%12.57M | -75.67%12.68M | -63.98%16.14M |
Net income continuous Operations | 25.29%50.37M | 380.80%3.35M | 87.78%23.61M | -24.94%9.52M | -13.93%13.89M | -72.68%40.2M | -111.01%-1.19M | -68.08%12.57M | -75.67%12.68M | -63.98%16.14M |
Minority interest income | 0 | |||||||||
Net income attributable to the parent company | 25.29%50.37M | 380.80%3.35M | 87.78%23.61M | -24.94%9.52M | -13.93%13.89M | -72.68%40.2M | -111.01%-1.19M | -68.08%12.57M | -75.67%12.68M | -63.98%16.14M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 25.29%50.37M | 380.80%3.35M | 87.78%23.61M | -24.94%9.52M | -13.93%13.89M | -72.68%40.2M | -111.01%-1.19M | -68.08%12.57M | -75.67%12.68M | -63.98%16.14M |
Basic earnings per share | 24.86%2.21 | 400.00%0.15 | 87.27%1.03 | -25.00%0.42 | -14.08%0.61 | -72.60%1.77 | -110.42%-0.05 | -68.21%0.55 | -75.55%0.56 | -63.78%0.71 |
Diluted earnings per share | 25.71%2.2 | 400.00%0.15 | 87.27%1.03 | -23.64%0.42 | -12.86%0.61 | -72.57%1.75 | -110.64%-0.05 | -67.84%0.55 | -75.66%0.55 | -63.73%0.7 |
Dividend per share | 2.72%1.51 | 2.67%0.385 | 2.74%0.375 | 2.74%0.375 | 2.74%0.375 | 7.30%1.47 | 2.74%0.375 | 8.96%0.365 | 8.96%0.365 | 8.96%0.365 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |